Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 15, Number 8—August 2009

Increase in Pneumococcus Macrolide Resistance, United States

Stephen G. JenkinsComments to Author  and David J. Farrell
Author affiliations: Weill Cornell Medical College, New York, NY, USA (S.G. Jenkins); Quotient Bioresearch Ltd, London, UK (D.J. Farrell)

Main Article

Table 2

Macrolide resistance genotypes, year 5 (2004-2005) and year 6 (2005–2006) of the PROTEKT US surveillance study*

   Genotype    No. isolates (% of ERSP)†
   Year 5 (n = 1,907)    Year 6 (n = 2,381)
   erm(B)    310 (16.3)    448 (18.8)
   mef(A)    1,172 (61.5)    1,282 (53.8)
   erm(B) + mef(A)    377 (19.8)    575 (24.1)
   erm(TR)    2 (0.1)    0
   Ribosomal mutations    26 (1.4)    41 (1.7)

   *PROTEKT US, Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin, United States; ERSP, erythromycin-resistant Streptococcus pneumoniae.
   †A total of 20 isolates in year 5 and 35 isolates in year 6 were not viable for genotyping.

Main Article

Page created: September 07, 2012
Page updated: September 07, 2012
Page reviewed: September 07, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.